Chronic Myelogenous Leukemia Treatment Market Expected To Reach US$ 8,550.8 Mn By 2026

Majorly, chronic myelogenous leukemia (CML) occurs in adults, however, it sometimes occurs in
children as well. However, targeted drugs called Tyrosine-Kinase Inhibitors (TKIs) have been
effective in providing long-term survival rates. Meanwhile, the Food and Drug Administration
(FDA) has recently approved dasatinib (Sprycel) for the treatment of chronic myelogenous
leukemia in children. As the chronic myeloid leukemia is more aggressive in younger patients, the
approval of drugs can help in effective treatment.
Some of the factors such as a rise in research and development in oncology sector, innovation in
drug development, new products in the pipeline, and the establishment of novel therapies are
resulting in the growth of the global chronic myelogenous leukemia market. However, the high cost
of treatment is one of the biggest factor hampering the growth of the global chronic myelogenous
leukemia market.
Some of the key players included in the report are Novartis, Bristol Myers Squibb, Pfizer, HoffmanLaRoche and Schering Plough, Teva Pharmaceutical, and Others. The key players are entering into
the mergers and acquisitions, partnerships, for new product launches and to expand geographically.
Global Chronic Myelogenous Leukemia Treatment Market to Witness Robust Growth during the
forecast period 2017-2026
Read Report Overview @
As per the latest report by Transparency Market Research (TMR), the global chronic myelogenous
leukemia market is expected to witness strong growth. The market is estimated to register 6.7%
CAGR during the forecast period 2017-2026. It is also expected to reach US$ 8,550.8 million
revenue by the end of 2026.
The global chronic myelogenous leukemia market is segmented on the basis of drug type, treatment
type, distribution channel, and region. Based on the drug type, the market segment includes generic
and branded drug. Among these, Branded drugs are expected to account for highest revenue share.
On the basis of treatment type, the segment includes symptomatic treatment and disease specific
treatment. During the forecast period 2017-2026, disease specific treatment is expected to witness
significant growth.
Based on the distribution channel, the market is categorized into specialty pharmacies, hospital
pharmacies, and retail pharmacies. Hospital pharmacies are expected to be the largest distribution
channel during the forecast period 2017-2026. Region-wise, the segmentation includes North
America, Latin America, Europe, Japan, Asia Pacific Excluding Japan (APEJ), and the Middle East
and Africa (MEA). North America is expected to remain dominant in the global chronic
myelogenous leukemia market through 2026.
New Class of Drugs to Revolutionize the Treatment of Chronic Myelogenous Leukemia
Chronic myelogenous leukemia is a type of blood cancer that cannot be cured with normal
treatments. Hence, a new class of drugs known as Tyrosine-Kinase Inhibitors (TKIs) has been
developed that is resulting in the more effective treatment of CML. These class of drugs is also
known as BCR-ABL inhibitors. Imatinib, which is known as first generation TKI, is quickly
becoming a standard treatment for chronic myelogenous leukemia. Meanwhile, Nilotinib is a
second generation TKI which is being used by patients who are no longer able to respond to
imatinib. TKIs are expensive, hence, generic imatinibs have also been introduced in various
countries. The biggest restricting factor in the use of TKIs is the high cost of these drugs. TKIs,
including imatinib drug, is effective at killing leukemic cells, but still is not able to kill the CML
cells from which the disease is born. Hence, new research is also being carried out for more
advanced and effective treatment.
Request Sample Report @
About Us
Transparency Market Research (TMR) is a global market intelligence company providing business
information reports and services. The company’s exclusive blend of quantitative forecasting and
trend analysis provides forward-looking insight for thousands of decision makers. TMR’s
experienced team of analysts, researchers, and consultants use proprietary data sources and various
tools and techniques to gather and analyze information.
TMR’s data repository is continuously updated and revised by a team of research experts so that it
always reflects the latest trends and information. With extensive research and analysis capabilities,
Transparency Market Research employs rigorous primary and secondary research techniques to
develop distinctive data sets and research material for business reports.
Contact Us
Transparency Market Research
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: [email protected]